Median Technologies' eyonis® LCS Secures CE Mark for European Lung Cancer Screening Expansion — Median Technologies SA

Event summary

Median Technologies' eyonis® LCS received CE marking as a Class IIb medical device under the European Medical Device Regulation (MDR 2017/745), enabling commercialization across the European Economic Area.
The AI-powered Software as a Medical Device (SaMD) demonstrated 93.3% sensitivity and 92.4% specificity, significantly outperforming traditional screening methods.
eyonis® LCS achieved a 68% reduction in false positives and a 66% reduction in false negatives compared to unaided radiologists.
The CE marking follows the FDA clearance obtained in February 2026, expanding access to Median’s AI-based SaMD for lung cancer screening.

The big picture

Median Technologies' CE marking for eyonis® LCS positions it as a key player in Europe's accelerating lung cancer screening market. With an estimated 25 to 30 million eligible individuals across the EU, the company is well-suited to support healthcare systems in scaling screening programs with enhanced accuracy and efficiency. The strategic anomaly here is the rapid transition from pilot programs to national deployment, creating a strong foundation for scalable, technology-driven solutions like eyonis® LCS.

What we're watching

Market Adoption: How the pace of European lung cancer screening program deployments will affect eyonis® LCS adoption.
Competitive Positioning: Whether Median can sustain its clinical advantage over existing AI-based solutions in lung cancer screening.
Regulatory Dynamics: The impact of evolving medical device regulations on the scalability of AI-powered diagnostic tools.